Sabin Vaccine Institute Archives | Page 2 of 2

Sabin Vaccine Institute Receives $20.5 Million from BARDA with Potential of Up to $128 Million to Develop Ebola Sudan and Marburg Vaccines

WASHINGTON, Oct. 1 (Korea Bizwire) — The Sabin Vaccine Institute (Sabin) today announced a funding award of $20.5 million with options for an additional $107.5 million from the Biomedical Advanced Research and Development Authority (BARDA) within the U.S. Department of Health and Human Services. Under the terms of this agreement, the full program is expected [...]

GSK Grants Exclusive Technology License for Clinical-Stage Ebola Vaccines to Sabin Vaccine Institute

LONDON and WASHINGTON, Aug. 6 (Korea Bizwire) — GSK and the Sabin Vaccine Institute (Sabin) today announced exclusive agreements for Sabin to advance the development of the prophylactic candidate vaccines against the deadly Ebola Zaire, Ebola Sudan and the closely related, but lesser known, Marburg virus. No licensed vaccines against these three viruses are currently [...]